Vacidox

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vacidox

What is Vacidox?

Vacidox is a pharmaceutical formulation containing the active ingredient doxycycline, which belongs to the tetracycline class of antibiotics. It is primarily used to treat a wide range of bacterial infections by inhibiting the ability of bacteria to produce essential proteins necessary for their growth and reproduction.

Mechanism of Action

The active component in Vacidox works by binding to the 30S ribosomal subunit of susceptible bacteria. This action prevents the addition of amino acids to the growing peptide chain, effectively halting protein synthesis. Because it targets processes specific to bacterial cells, it is classified as a bacteriostatic agent, meaning it prevents the multiplication of bacteria rather than killing them outright, allowing the body's immune system to eliminate the remaining pathogen.

Common Applications

Vacidox is utilized in the management of various conditions, including:

  • Respiratory Tract Infections: Such as pneumonia and chronic bronchitis.
  • Dermatological Conditions: Specifically inflammatory acne and rosacea.
  • Urinary Tract Infections: Caused by susceptible strains of bacteria.
  • Vector-Borne Diseases: Including Lyme disease, Rocky Mountain spotted fever, and certain types of typhus.
  • Other Infections: It may also be used for the prevention of malaria in specific geographic regions and for the treatment of certain sexually transmitted infections.

Characteristics

Unlike earlier tetracyclines, the formulation of doxycycline found in Vacidox is highly lipophilic, which allows it to penetrate various body tissues and fluids effectively. It also possesses a longer half-life, which generally permits less frequent administration compared to older generation antibiotics in the same class.

Regulatory References

  1. estrogen deficiency
  2. U.S. National Library of Medicine

What side effects are possible with Vacidox?

Safety Information and Potential Side Effects

Vacidox (a systemic fluoroquinolone antibiotic) carries a Boxed Warning—the strongest warning required by the FDA—due to the risk of disabling and potentially permanent side effects that can involve the tendons, muscles, joints, nerves, and central nervous system (CNS).

These serious adverse reactions may occur together and can manifest rapidly, from hours to weeks after starting the medicine. They include:

  • Musculoskeletal and Peripheral Nervous System: Tendinitis, tendon rupture (most commonly the Achilles tendon), peripheral neuropathy (nerve damage) presenting as numbness, tingling, pricking sensation, muscle weakness, or joint pain/swelling.
  • Central Nervous System (CNS): Psychiatric effects, including anxiety, depression, insomnia, hallucinations, psychosis, confusion, and suicidal thoughts.
  • Other Serious Risks: Exacerbation of myasthenia gravis, prolongation of the QT interval (a serious cardiac rhythm effect), hypersensitivity reactions, phototoxicity, and blood glucose disturbances.

Safety Restrictions and Limitations

Official regulatory documents from the FDA state that the serious risks of Vacidox generally outweigh the benefits for patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections (UTIs). The drug should only be reserved for these conditions when no other treatment options are available. The serious side effects may persist for months or become permanent even after discontinuing the drug.

Common Adverse Reactions

Commonly reported side effects include nausea, diarrhea, headache, dizziness, lightheadedness, or trouble sleeping.

Overdose and Emergency Response

Overdose Manifestations and Immediate Actions

The official regulatory documents define the overdose profile for Estriol by focusing on exaggerated, yet generally transient, hormonal effects. Manifestations are typically indicative of a dosage that is too high, rather than a medically severe outcome. The risks associated with systemic estrogen therapy are officially noted to apply to a lesser extent for this local preparation.

Documented Signs of Overdose:

  • Vaginal bleeding (metrorrhagia)
  • Breast tenderness or swelling
  • Nausea
  • Fluid retention (e.g., swollen ankles or feet)

When to Seek Urgent Medical Help: Immediate medical attention is required following the accidental ingestion of a large quantity of the product. Regulator guidance advises contacting a poison control center or emergency room at once in this situation.

Required Regulatory Actions: If symptoms indicative of overdose (such as vaginal bleeding or breast tenderness) are observed, the immediate discontinuation of the medicine is the mandated action. The overall management of overdose is defined as symptomatic treatment to address the effects observed. While no specific antidote is listed in official labeling, procedural steps may include the consideration of gastric emptying by a healthcare professional after accidental bulk ingestion.

Therapeutic Uses of Vacidox

What Vacidox Treats: Main Uses and Benefits

Vacidox is used to provide symptomatic relief and supportive therapeutic benefit across domains involving certain distressing symptoms related to inflammatory or irritative states. It assists with managing symptoms that may interfere with daily functioning and quality of life.

The application of local therapy is used for managing symptoms associated with certain chronic conditions, a state that presents with physical discomfort, including dryness and irritation.

The medication is commonly used to help address symptom clusters that include chronic vaginal and vulvar discomfort, symptoms related to physical discomfort during sexual activity, and associated urogenital irritation. It is applied in scenarios where additional management of discomfort is required to ease the overall symptom burden.

“This supportive relief may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.”

Quick Fact: Support for Chronic Irritation

Vacidox is commonly used for managing conditions characterized by periods of heightened symptoms such as persistent burning or soreness. It provides supportive assistance that helps improve day-to-day comfort during these periods.

Eligibility and Restrictions for Use

Population Eligibility for Vacidox (Estriol)

Official regulatory documents define strict eligibility criteria for the use of Estriol-based medications, focusing primarily on the patient’s age, reproductive status, and medical history.

Eligible and Restricted Populations

Category Eligibility Rule Regulatory Status
Target Group Adult postmenopausal women with local symptoms of estrogen deficiency. Permitted
Lactation Women who are breastfeeding. Not Recommended
Pediatric Use Children and adolescents. Not Established/Not Indicated

Absolute Contraindications

Vacidox is strictly contraindicated (must not be used) in individuals with the following conditions, as stated in official labeling:

  • Known, suspected, or history of estrogen-dependent malignant tumors (e.g., breast cancer, endometrial cancer).
  • Previous or current thromboembolic disease (e.g., DVT, PE, stroke, or myocardial infarction).
  • Acute liver disease or unrecovered impaired liver function.
  • Presence of undiagnosed abnormal genital bleeding.
  • Pregnancy (use is contraindicated if a woman is pregnant).

What should I know about interactions with other medicines?

Vacidox Interactions with other medicines and products

Official regulatory information for Vacidox (Estriol) defines interactions based on two primary effects: alteration of drug exposure and changes in hormone-binding proteins.

Interactions Affecting Drug Exposure

The active ingredient in Vacidox is partially metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with substances that modify this enzyme is documented to alter Estriol's plasma concentration. This interaction is classified as pharmacokinetic.

Interaction Type Examples of Interacting Substances Regulatory Outcome Statement
Exposure-Reducing (CYP3A4 Inducers) Phenobarbital, Carbamazepine, Rifampin, St. John's Wort Documented to reduce Estriol plasma concentrations
Exposure-Increasing (CYP3A4 Inhibitors) Ketoconazole, Ritonavir, Clarithromycin, Grapefruit juice Documented to increase Estriol plasma concentrations

Pharmacodynamic Interaction

Estriol can cause an officially documented increase in the hepatic synthesis of Thyroid-Binding Globulin (TBG). This change in binding protein levels may affect the circulating level of free thyroid hormone, which is a specific consideration when Estriol is co-administered with Thyroid Replacement Therapy (e.g., Levothyroxine). The regulatory text notes this effect as a relevant interaction.

Interaction-Related Constraints

No mandatory time separation rules between doses are formally stated in regulatory documents based on interaction risk. Although no specific drug-drug combination is formally designated as a contraindication solely due to interaction, Known liver impairment or disease is listed as a contraindication for estrogen products, reflecting a caution related to the drug's hepatic clearance pathway.

Mechanism of Action

Vacidox is an estrogen receptor (ER) agonist. Its primary biological targets are the nuclear estrogen receptors, specifically the alpha (ERalpha) and beta (ERbeta) subtypes, where it functions as a ligand. Upon binding to the cytosolic ERs, the complex undergoes a conformational change and translocates into the cell nucleus. Intracellularly, the drug-receptor complex interacts with specific DNA sequences known as Estrogen Response Elements (EREs) in the promoter regions of target genes. This protein-DNA interaction modulates gene transcription, resulting in an alteration in the messenger RNA (mRNA) production for various proteins.

The subsequent downstream cascade involves the synthesis of specific proteins responsible for cell differentiation, proliferation, and maintenance of tissue structure in estrogen-sensitive tissues, such as the vaginal epithelium and urinary tract. This action maintains and modulates the functional integrity and physiological environment of these system-level structures.

Dosage and Administration Information

How to Use Vacidox

Vacidox (Estriol) is administered according to a specific schedule to provide localized hormonal support. The primary route of delivery for the cream and pessary formulations is intravaginal, which is intended to concentrate the weak estrogen action at the target site while limiting its systemic absorption. Administration of the cream requires the use of a calibrated applicator to ensure the correct unit dose is delivered. The standard unit dose is 0.5 mg of Estriol per application.


Administration Schedule and Pattern

The treatment is organized into two distinct phases: an initial loading period and a maintenance regimen. The purpose of this structure is to achieve tissue restoration with higher initial frequency before transitioning to a reduced pattern.

Usage Phase Standard Dosing Regimen Frequency and Duration Time of Use
Initial/Loading 0.5 mg of Estriol Once daily for up to 4 weeks At bedtime
Maintenance 0.5 mg of Estriol Twice weekly At bedtime

Procedural and Population Guidance

Administration is generally recommended to occur at bedtime to optimize retention and consistency. For patients scheduled for vaginal surgery, the regimen involves 0.5 mg once daily for the 14 days prior to the operation, followed by the twice-weekly maintenance dose post-procedure. The treatment is intended for continuous long-term use at the maintenance dose for as long as hormonal support is necessary, based on clinical context.

In the event of a missed dose: if remembered, the dose should be administered immediately, unless it is more than 12 hours past the scheduled time. Two doses should not be administered on the same day. Dosing for older adults typically follows the standard adult regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vacidox (Estriol)

Evidence for Genitourinary Syndrome of Menopause (GSM)

Studies evaluating Estriol for symptoms like vaginal dryness, irritation, and pain during sexual activity (dyspareunia) have primarily used Randomized Controlled Trials (RCTs). These studies were designed to monitor the effects over short-term observation periods in postmenopausal women with symptoms of atrophy. Researchers examined two main types of outcomes: patient-reported experiences, measured using standardized symptom severity scales, and objective biological markers.

Findings describe patterns observed in these studies, including shifts in the vaginal environment, such as movement toward a lower, more acidic vaginal pH. This finding describes objective biological measurements. Trials also documented changes in the Vaginal Maturation Index (VMI), which tracks cellular characteristics. These changes were observed in the lining of the vaginal wall. Studies reported how symptoms evolved in the observed populations during the short-term study periods.

Evidence for Lower Urinary Tract Symptoms and Recurrence

Estriol was studied for lower urinary tract symptoms, particularly research examining the frequency of recurrent urinary tract infections (UTIs) in postmenopausal women. Research examined the vaginal environment in the context of urinary tract function.

Large-scale retrospective studies monitored patient cohorts and reported patterns where the number of documented infection episodes was lower over the year following the start of treatment, compared to the year prior. Furthermore, studies monitored the vaginal environment and reported shifts in the bacterial balance (microbiome). The relationship between these shifts and infection frequency is not fully established and requires further study.

Research Gaps and Areas of Uncertainty

While a solid body of research exists, there are acknowledged limitations and areas where research is ongoing: Long-term outcomes beyond the first year of therapy are not well-characterized by large, dedicated clinical trials. Comparative evidence is lacking in some areas, particularly concerning head-to-head comparisons of Estriol against certain other available local estrogen products for long-term observation. Subgroup findings are uncertain in populations like women with specific pre-existing comorbidities, meaning results apply only to the populations studied in the original trials.

Key Studies & References

  1. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections - PubMed

Frequently Asked Questions (FAQ)

Common questions about Vacidox (FAQ)


Q: Is Vacidox the same as the older medicine for the same condition?

A: Vacidox contains the active ingredient Estriol, which is classified as a weak estrogen. It is chemically identical to the natural hormone produced by the body, which is why it is classified as 'bioidentical.' Official regulatory documents classify it as a medication for local hormonal support, often differentiating it from higher-potency forms of estrogen used for systemic therapy.

Q: Is it true that Vacidox only works for specific types of people?

A: According to official product indications, this medicine is specifically intended for adult postmenopausal women experiencing symptoms of estrogen deficiency, such as vaginal atrophy. Official information states that use in children and adolescents is not established.

Q: Can you take Vacidox if you are only taking vitamins or herbal supplements?

A: Official documents specifically warn about interactions with certain herbal supplements, such as St. John's Wort. Regulatory documents mention general caution, as the specific effects of many general vitamins or other herbal supplements on the medicine's action are not formally studied.

Q: Is it normal to feel a bit tired when starting Vacidox?

A: The official list of common side effects includes issues like dizziness or trouble sleeping. While specific fatigue or tiredness is not typically listed as a common adverse reaction in the product information, it is a symptom sometimes associated with hormone replacement therapies.

Q: What types of foods should be avoided when taking Vacidox?

A: Regulatory documents specifically list an interaction with grapefruit juice. This is because it can affect the way the body metabolizes (breaks down) the medicine, potentially increasing its effects. No other specific foods are consistently listed in official documents as contraindications.

Q: Do I need to take Vacidox with food, or can I take it anytime?

A: Official administration information advises using the local formulation at bedtime to optimize retention. Regulatory texts do not provide specific guidance mandating whether the local formulation must be taken with food or restrict taking it at other times of the day.

Q: Has Vacidox been approved in countries outside the US?

A: Yes, the active ingredient in Vacidox, Estriol, is referenced in regulatory documents from multiple international authorities, including the European Medicines Agency (EMA). It is widely approved and available for medical use in many countries globally.

Q: Is the condition Vacidox treats a chronic or temporary one?

A: The condition that Vacidox addresses, which includes symptoms of estrogen deficiency, is a long-term state associated with menopause. The medication is intended for continuous long-term use at the maintenance dose, which reflects the nature of the condition.

Q: Is it common for doctors to test blood levels while taking Vacidox?

A: Because the medicine is designed for localized delivery and has very low absorption into the general bloodstream, routine monitoring of estrogen blood levels is not typically indicated. However, monitoring procedures may vary if other systemic hormone products are being taken.

Q: Can I take other prescription medications at the same time as Vacidox?

A: Regulatory documents specify interactions with several classes of prescription medications, particularly those that affect the CYP3A4 enzyme system in the liver. These interactions include, but are not limited to, certain types of anticonvulsants and antifungals.

Q: Is Vacidox an antibiotic or an antiviral drug?

A: According to official sources, Vacidox is classified pharmacologically as a steroid hormone and an Estrogen medication. It is used as a hormone replacement therapy agent and does not belong to the classes of antibiotics or antiviral drugs.

Q: Why do some people call Vacidox a 'novel' treatment?

A: Official information notes that the active ingredient, Estriol, is a weak estrogen with a notably short duration of action and demonstrably low systemic absorption. This characteristic is a key differentiating factor when compared to other available estrogen products used for wider systemic effects.

Q: Does Vacidox work right away, or does it take time to feel a difference?

A: Clinical studies indicate that patients may experience initial improvement in symptoms like vaginal dryness and irritation within the first few weeks of starting treatment. Objective tissue changes are noted to continue throughout the initial treatment phase.

Q: Does Vacidox have any known interaction with common pain relievers?

A: Regulatory documents for the localized formulation do not contain specific warnings about interactions with common over-the-counter pain relievers like acetaminophen or ibuprofen.

Q: Is Vacidox considered a controlled substance or highly regulated?

A: The active ingredient, Estriol, is classified as a steroid hormone but is not scheduled as a controlled substance by the US Drug Enforcement Administration (DEA). Regulatory oversight focuses on its safety and efficacy as a prescription medicine.

Q: Does Vacidox affect your appetite or weight?

A: Official adverse reaction profiles for the local formulation do not typically list changes in appetite or weight. However, some hormone therapies are associated with fluid retention.

Q: What happens if Vacidox is taken with alcohol?

A: While regulatory texts for the local product do not list an acute interaction with alcohol, general guidance suggests that alcohol consumption may affect overall hormone metabolism.

Q: Are there official registry studies where patients can report their experience with Vacidox?

A: Like all prescription medicines, Vacidox is subject to regulatory oversight called pharmacovigilance. Official regulatory bodies maintain voluntary reporting systems where patients and healthcare providers can report their experiences and any observed adverse events.

Q: Does Vacidox interact with blood pressure medicine?

A: Regulatory documents mention that caution and monitoring may be necessary for patients with pre-existing cardiovascular conditions, as estrogens may potentially lead to fluid retention.

Q: If I have kidney problems, does that mean I cannot use Vacidox?

A: Severe liver dysfunction is classified as an absolute contraindication. In contrast, severe kidney problems are generally listed as a condition that warrants caution and monitoring during treatment.

Q: What is the general success rate mentioned in the clinical trials of Vacidox?

A: Clinical trials indicate that the active ingredient significantly improves patient-reported symptoms and objective biological markers, such as changes in vaginal pH. Official summaries typically report observed patterns of improvement in symptoms and objective markers, but they do not define a single, quantified 'general success rate' percentage.

Q: Does Vacidox show up on drug screening tests?

A: Estriol, the active ingredient, is a naturally occurring hormone and metabolite in the human body. Estriol is not typically included in standard drug screening tests, as these are usually designed to detect illicit substances or controlled medicines.

Q: Are there any known serious interactions with anti-depressants and Vacidox?

A: Regulatory documents advise caution with medications that affect the CYP3A4 enzyme system, as this system is responsible for metabolizing the medicine. Certain anti-depressants are known to inhibit this enzyme, which could potentially alter the medicine's exposure in the body.

Q: Is Vacidox safe to take with common allergy medications?

A: Official regulatory documents do not typically list common over-the-counter allergy medications (antihistamines) as major interacting substances with the local formulation.

Q: What is the purpose of the non-active ingredients listed in Vacidox?

A: The inactive ingredients are not medically active but are essential components like emollients, stabilizers, and the vehicle base (e.g., cream base). They ensure the product maintains the correct consistency, stability, and effective delivery of the active Estriol to the intended target tissue.

Q: Is it possible to develop a tolerance to Vacidox over time?

A: The development of tolerance (tachyphylaxis) is not listed as a known characteristic or risk for the local use of Estriol in regulatory information.

Q: How long does Vacidox stay in your system after stopping treatment?

A: Official pharmacokinetic information characterizes Estriol as a short-acting hormone with very low systemic absorption. The pharmacokinetic profile indicates that the active ingredient is cleared from the general bloodstream relatively quickly due to its short-acting nature and low systemic absorption.

Q: What is the risk of dependence or addiction with Vacidox?

A: Regulatory adverse event profiles do not list the risk of physical dependence or addiction as a potential side effect of the medicine. The active ingredient, Estriol, is also not classified as a controlled substance.

Q: What is the difference between brand-name Vacidox and generic versions?

A: In some regions, Estriol may not be available as a traditional prescription product approved by regulatory bodies like the FDA, meaning a conventional generic version is not produced. In regions where it is formally approved, the generic version would contain the same active ingredient as the brand-name product.

Q: Does Vacidox affect birth control pills?

A: Due to the localized method of application and the resulting low absorption into the general bloodstream, the risk of this medicine interfering with the effectiveness of systemic hormonal birth control pills is not listed as a major interaction in official documents.

Q: What are the restrictions on driving or operating machinery while taking Vacidox?

A: Official documents note that a small number of individuals may experience side effects such as dizziness or blurred vision. Patients experiencing these effects are generally advised to use caution before driving or operating machinery.

How should Vacidox be stored and disposed of?

The storage and disposal of Vacidox (Estriol) must comply with official regulatory guidelines to maintain its stability and ensure safety.

Storage Conditions

Vacidox must be stored at controlled room temperature, typically below 25°C or 30°C. It is mandatory to protect from light and to avoid freezing and excessive heat, as these conditions can damage the product form (cream/suppository). The medicine must be kept in its original container, which should remain tightly closed, and out of the sight and reach of children.


Disposal Instructions

Expired or unused Vacidox should not be disposed of in wastewater (sinks or toilets) or general household trash. The preferred method is to utilize an authorized drug take-back program or return the product to a pharmacy as dictated by local pharmaceutical regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vacidox found in:

A-Z Index: